Predictive value of molecular response on second-line therapy.
 For chronic-phase patients treated with nilotinib or dasatinib after imatinib failure the 3-month BCR-ABL value was predictive of a major molecular response (MMR). (A) Eighteen of the 155 patients included in the analysis already had an MMR at 3 months of therapy and were excluded. The 3-month BCR-ABL value was also predictive of a major cytogenetic response (MCR). (B) The 50 patients with values of ≤ 1.0% International Scale (IS) at 3 months already had an MCR.